Journal article Open Access

Adverse effects of anticancer agents that target the VEGF pathway

Chen, Helen X.; Cleck, Jessica N.


Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Chen, Helen X.</dc:creator>
  <dc:creator>Cleck, Jessica N.</dc:creator>
  <dc:date>2009-07-07</dc:date>
  <dc:description>Antiangiogenic agents that target the VEGF pathway have become an important part of standard therapy in multiple cancer indications. Although most adverse effects of VEGF inhibitors are modest and manageable, some are associated with serious and life-threatening consequences. This Review examines the toxicity profiles of anti-VEGF monoclonal antibodies and small-molecule inhibitors and considers the potential mechanisms of the adverse effects, risk factors, and the implications for patient management.</dc:description>
  <dc:identifier>https://zenodo.org/record/1233504</dc:identifier>
  <dc:identifier>10.1038/nrclinonc.2009.94</dc:identifier>
  <dc:identifier>oai:zenodo.org:1233504</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://creativecommons.org/publicdomain/zero/1.0/legalcode</dc:rights>
  <dc:title>Adverse effects of anticancer agents that target the VEGF pathway</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>
125
122
views
downloads
Views 125
Downloads 122
Data volume 52.7 MB
Unique views 118
Unique downloads 109

Share

Cite as